title: B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
abstract: B7-H3 belongs to the co-inhibitory B7 family and plays an important role in the adaptive immune response in regulating T cells. In human malignancies, B7-H3 is reported to be involved in tumor immune evasion. However, the detailed molecular mechanism of B7-H3 in tumor evasion remains unclear, particularly in non-small cell lung cancer (NSCLC). Regulatory T cells (Tregs) are known as a key player in the inhibition of immune mechanisms. The study demonstrated the correlation between B7-H3 on tumor cells and the number of Tregs in the tumor microenvironment in NSCLC. B7-H3 was examined in tumor tissues from 110 patients with NSCLC by immunohistochemical analysis. Forkhead box P3+ (FOXP3+) Tregs in those spencimens were also detected and numbered. Survival curves were drawn using the Kaplan-Meier method and compared by the log-rank test. High B7-H3 expression in tumor cells significantly correlated with male gender, squamous NSCLC, advanced stage and shorter overall survival (OS) (P = 0.035, P = 0.004, P = 0.037, P = 0.014, respectively). Meanwhile, FOXP3 expression in tumor-infiltrating lymphocytes (TILs) was associated with male gender, regional lymph node involvement, advanced stage and worse OS (P = 0.009, P = 0.015, P = 0.014, P = 0.034, respectively). Significant correlation was identified between the expression of B7-H3 and the number of FOXP3+ TILs (P = 0.013). Patients with B7-H3 high/FOXP3 high had poorer OS (P = 0.006), suggesting that B7-H3 and Tregs may play a cooperatively role in tumor immune evasion, leading to poor outcomes for NSCLC patients.
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong UniversityJinan 250013, Shandong, P. R. China; Department of Oncology, Zhangqiu HospitalZhangqiu, 250200, Shandong, P. R. China.
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Jin
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Pei
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Jianqiang
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Chuanyong
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Pathology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Fei
authors.initials: F
authors.lastname: Yang
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Dong
authors.initials: D
authors.lastname: Yang
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Aiqin
authors.initials: A
authors.lastname: Gao
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Wenli
authors.initials: W
authors.lastname: Lin
authors.affiliation: Department of Gastroscopy Center, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, P. R. China.
authors.forename: Yuping
authors.initials: Y
authors.lastname: Sun
mesh_terms: D060887:B7 Antigens / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D018791:CD4 Lymphocyte Count; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016009:Chi-Square Distribution; D018450:Disease Progression; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012307:Risk Factors; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000473:pathology; D013997:Time Factors; D019139:Tumor Escape; D059016:Tumor Microenvironment
chemical_list: D060887:B7 Antigens; D014408:Biomarkers, Tumor; C423237:CD276 protein, human; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors
keywords: B7-H3; non-small cell lung cancer; regulatory T cell; tumor immune evasion
references.citation: Immunol Rev. 2009 May;229(1):145-51
references.pmid: 19426220
references.citation: Biochem Biophys Res Commun. 2013 Aug 23;438(2):439-44
references.pmid: 23916610
references.citation: Lung Cancer. 2014 Aug;85(2):101-9
references.pmid: 24880938
references.citation: Cancer. 2006 Dec 15;107(12):2866-72
references.pmid: 17099880
references.citation: J Immunol. 2002 May 1;168(9):4272-6
references.pmid: 11970966
references.citation: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references.pmid: 22700443
references.citation: Int J Cancer. 2012 Dec 1;131(11):2528-36
references.pmid: 22473715
references.citation: Int Immunopharmacol. 2014 Feb;18(2):255-61
references.pmid: 24345703
references.citation: J Invest Dermatol. 2013 Aug;133(8):2050-8
references.pmid: 23474948
references.citation: Mol Clin Oncol. 2014 Sep;2(5):685-694
references.pmid: 25054031
references.citation: Lancet. 2013 Aug 24;382(9893):709-19
references.pmid: 23972814
references.citation: Cancer Immunol Immunother. 2012 Aug;61(8):1327-41
references.pmid: 22695874
references.citation: Mol Med Rep. 2013 Jan;7(1):134-8
references.pmid: 23128494
references.citation: Int J Mol Med. 2013 Feb;31(2):283-91
references.pmid: 23242015
references.citation: Cancer Res. 2007 Aug 15;67(16):7893-900
references.pmid: 17686830
references.citation: Curr Opin Immunol. 2015 Apr;33:101-11
references.pmid: 25728990
references.citation: Int J Cancer. 2012 May 15;130(10):2282-90
references.pmid: 21671471
references.citation: Saudi Med J. 2010 Sep;31(9):980-6
references.pmid: 20844808
references.citation: Br J Cancer. 2014 Apr 15;110(8):2072-80
references.pmid: 24577056
references.citation: BMC Cancer. 2014;14:602
references.pmid: 25139714
references.citation: Lung Cancer. 2006 Aug;53(2):143-51
references.pmid: 16782226
references.citation: Nat Immunol. 2001 Mar;2(3):269-74
references.pmid: 11224528
references.citation: Nat Rev Immunol. 2004 Nov;4(11):889-99
references.pmid: 15516968
references.citation: Nat Rev Immunol. 2006 Apr;6(4):295-307
references.pmid: 16557261
references.citation: Cancer J. 2014 Jul-Aug;20(4):290-5
references.pmid: 25098290
references.citation: Lung Cancer. 2012 Jan;75(1):95-101
references.pmid: 21719142
references.citation: Int Immunol. 2004 Nov;16(11):1643-56
references.pmid: 15466453
references.citation: Int J Cancer. 2014 Jun 15;134(12):2764-71
references.pmid: 24013874
references.citation: Trends Immunol. 2013 Nov;34(11):556-63
references.pmid: 23954143
references.citation: Clin Lung Cancer. 2013 Mar;14(2):157-63
references.pmid: 22868219
references.citation: Oncol Lett. 2013 Nov;6(5):1253-1260
references.pmid: 24179504
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Nat Immunol. 2003 Sep;4(9):899-906
references.pmid: 12925852
references.citation: Front Biosci (Elite Ed). 2011;3:989-93
references.pmid: 21622107
references.citation: J Clin Invest. 2004 Nov;114(9):1209-17
references.pmid: 15520849
references.citation: Semin Cancer Biol. 2015 Dec;35 Suppl:S185-98
references.pmid: 25818339
references.citation: Clin Cancer Res. 2012 Jun 1;18(11):3022-9
references.pmid: 22510350
references.citation: Int J Cancer. 2012 Oct 1;131(7):E1055-66
references.pmid: 22467332